See more : Scape Technologies A/S (SCAPE.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Embecta Corp. (EMBC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Embecta Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shanghai New Power Automotive Technology Company Limited (600841.SS) Income Statement Analysis – Financial Results
- Smart Eye AB (publ) (SEYE.ST) Income Statement Analysis – Financial Results
- Samvardhana Motherson International Limited (MOTHERSON.NS) Income Statement Analysis – Financial Results
- EZTD Inc. (EZTD) Income Statement Analysis – Financial Results
- Yakult Honsha Co.,Ltd. (YKLTF) Income Statement Analysis – Financial Results
Embecta Corp. (EMBC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.embecta.com
About Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1.12B | 1.12B | 1.13B | 1.17B | 1.09B | 1.11B |
| Cost of Revenue | 387.90M | 370.90M | 354.60M | 365.00M | 322.90M | 323.00M |
| Gross Profit | 735.20M | 749.90M | 774.90M | 800.00M | 762.60M | 786.00M |
| Gross Profit Ratio | 65.46% | 66.91% | 68.61% | 68.67% | 70.25% | 70.87% |
| Research & Development | 78.80M | 85.20M | 66.90M | 63.00M | 61.40M | 62.00M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | -300.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 240.00M | 215.00M | 222.00M |
| SG&A | 365.10M | 341.30M | 294.80M | 240.00M | 214.70M | 222.00M |
| Other Expenses | 124.50M | 101.90M | 44.70M | 5.00M | -700.00K | -2.00M |
| Operating Expenses | 568.40M | 528.40M | 406.40M | 308.00M | 276.10M | 284.00M |
| Cost & Expenses | 956.30M | 899.30M | 761.00M | 673.00M | 599.00M | 607.00M |
| Interest Income | 0.00 | 0.00 | 46.20M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 112.30M | 107.00M | 46.20M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 36.20M | 32.60M | 31.70M | 38.00M | 38.00M | 36.00M |
| EBITDA | 199.00M | 245.40M | 400.20M | 530.00M | 524.00M | 538.00M |
| EBITDA Ratio | 17.72% | 21.90% | 34.83% | 45.49% | 48.28% | 48.51% |
| Operating Income | 166.80M | 221.50M | 309.60M | 492.00M | 486.50M | 502.00M |
| Operating Income Ratio | 14.85% | 19.76% | 27.41% | 42.23% | 44.82% | 45.27% |
| Total Other Income/Expenses | -122.60M | -115.80M | -53.00M | 3.00M | -700.00K | -2.00M |
| Income Before Tax | 44.20M | 105.70M | 256.60M | 495.00M | 485.80M | 500.00M |
| Income Before Tax Ratio | 3.94% | 9.43% | 22.72% | 42.49% | 44.75% | 45.09% |
| Income Tax Expense | -34.10M | 35.30M | 33.00M | 80.00M | 58.20M | 68.00M |
| Net Income | 78.30M | 70.40M | 223.60M | 414.80M | 427.60M | 432.00M |
| Net Income Ratio | 6.97% | 6.28% | 19.80% | 35.61% | 39.39% | 38.95% |
| EPS | 1.36 | 1.23 | 3.92 | 7.31 | 7.50 | 7.58 |
| EPS Diluted | 1.34 | 1.22 | 3.92 | 7.31 | 7.50 | 7.58 |
| Weighted Avg Shares Out | 0.00 | 57.24M | 57.06M | 56.80M | 57.00M | 57.00M |
| Weighted Avg Shares Out (Dil) | 0.00 | 57.76M | 57.06M | 56.80M | 57.00M | 57.00M |
New Initiatives Expected To Make Embecta More Profitable
New Strong Buy Stocks for December 2nd
Best Value Stocks to Buy for December 2nd
Best Income Stocks to Buy for December 2nd
Overlooked Stock: EMBC
Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs
embecta Announces Quarterly Cash Dividend
Source: https://incomestatements.info
Category: Stock Reports